Long-term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study,Neuroendocrinology

当前位置： X-MOL 学术 › Neuroendocrinology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Long-term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study
Neuroendocrinology ( IF 3.2 ) Pub Date : 2021-05-03 , DOI: 10.1159/000516958
Dieter Hörsch ₁ , Lowell Anthony ₂ , David J Gross ₃ , Juan W Valle ₄ , Staffan Welin ₅ , Marta Benavent ₆ , Martyn Caplin ₇ , Marianne Pavel ₈ , Emily Bergsland ₉ , Kjell Öberg ₅ , Kenneth B Kassler-Taub ₁₀ , Polina Binder ₁₀ , Phillip Banks ₁₀ , Pablo Lapuerta ₁₀ , Matthew H Kulke ₁₁

Affiliation

Department of Gastroenterology/Endocrinology, Center for Neuroendocrine Tumors, Zentralklinik Bad Berka, Bad Berka, Germany.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Neuroendocrine Tumor Unit, Department of Medicine, Endocrine Service, European Neuroendocrine Tumor Society Center of Excellence, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
University of Manchester/The Christie NHS Foundation Trust, Manchester, United Kingdom.
Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden.
Medical Oncology Department, Virgen del Rocío University Hospital/Instituto de Biomedicina de Sevilla, Seville, Spain.
Department of Gastroenterology & Hepatobiliary Medicine, Royal Free Hospital, Pond Street Centre for Gastroenterology, London, United Kingdom.
Department of Gastroenterology and Hepatology, Charité-Universitätsmedizin, Berlin, Germany.
Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California, USA.
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.
Section of Hematology/Oncology, Boston University and Boston Medical Center, Boston, Massachusetts, USA.